Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(11):1416–1418. doi: 10.1038/bjc.1997.572

Prognostic value of loss of heterozygosity at BRCA2 in human breast carcinoma.

I Bièche 1, C Noguès 1, S Rivoilan 1, A Khodja 1, A Latil 1, R Lidereau 1
PMCID: PMC2228174  PMID: 9400936

Abstract

To confirm several recent studies pointing to loss of heterozygosity (LOH) at BRCA2 as a prognostic factor in sporadic breast cancer, we examined this genetic alteration in a large series of human primary breast tumours for which long-term patient outcomes were known. LOH at BRCA2 correlated only with low oestrogen and progesterone receptor content. Univariate analysis of metastasis-free survival and overall survival (log-rank test) showed no link with BRCA2 status (P = 0.34, P = 0.29 respectively). LOH at BRCA2 does not therefore appear to be a major prognostic marker in sporadic breast cancer.

Full text

PDF
1416

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beckmann M. W., Picard F., An H. X., van Roeyen C. R., Dominik S. I., Mosny D. S., Schnürch H. G., Bender H. G., Niederacher D. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br J Cancer. 1996 May;73(10):1220–1226. doi: 10.1038/bjc.1996.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bignon Y. J., Fonck Y., Chassagne M. C. Histoprognostic grade in tumours from families with hereditary predisposition to breast cancer. Lancet. 1995 Jul 22;346(8969):258–258. doi: 10.1016/s0140-6736(95)91310-6. [DOI] [PubMed] [Google Scholar]
  3. Bièche I., Lidereau R. Genetic alterations in breast cancer. Genes Chromosomes Cancer. 1995 Dec;14(4):227–251. doi: 10.1002/gcc.2870140402. [DOI] [PubMed] [Google Scholar]
  4. Chen Y., Chen C. F., Riley D. J., Allred D. C., Chen P. L., Von Hoff D., Osborne C. K., Lee W. H. Aberrant subcellular localization of BRCA1 in breast cancer. Science. 1995 Nov 3;270(5237):789–791. doi: 10.1126/science.270.5237.789. [DOI] [PubMed] [Google Scholar]
  5. Cleton-Jansen A. M., Collins N., Lakhani S. R., Weissenbach J., Devilee P., Cornelisse C. J., Stratton M. R. Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. Br J Cancer. 1995 Nov;72(5):1241–1244. doi: 10.1038/bjc.1995.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Couch F. J., Farid L. M., DeShano M. L., Tavtigian S. V., Calzone K., Campeau L., Peng Y., Bogden B., Chen Q., Neuhausen S. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996 May;13(1):123–125. doi: 10.1038/ng0596-123. [DOI] [PubMed] [Google Scholar]
  7. Hamann U., Herbold C., Costa S., Solomayer E. F., Kaufmann M., Bastert G., Ulmer H. U., Frenzel H., Komitowski D. Allelic imbalance on chromosome 13q: evidence for the involvement of BRCA2 and RB1 in sporadic breast cancer. Cancer Res. 1996 May 1;56(9):1988–1990. [PubMed] [Google Scholar]
  8. Kelsell D. P., Spurr N. K., Barnes D. M., Gusterson B., Bishop D. T. Combined loss of BRCA1/BRCA2 in grade 3 breast carcinomas. Lancet. 1996 Jun 1;347(9014):1554–1555. doi: 10.1016/s0140-6736(96)90707-2. [DOI] [PubMed] [Google Scholar]
  9. Kerangueven F., Allione F., Noguchi T., Adélaïde J., Sobol H., Jacquemier J., Birnbaum D. Patterns of loss of heterozygosity at loci from chromosome arm 13q suggests a possible involvement of BRCA2 in sporadic breast tumors. Genes Chromosomes Cancer. 1995 Aug;13(4):291–294. doi: 10.1002/gcc.2870130410. [DOI] [PubMed] [Google Scholar]
  10. Lancaster J. M., Wooster R., Mangion J., Phelan C. M., Cochran C., Gumbs C., Seal S., Barfoot R., Collins N., Bignell G. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet. 1996 Jun;13(2):238–240. doi: 10.1038/ng0696-238. [DOI] [PubMed] [Google Scholar]
  11. Miki Y., Katagiri T., Kasumi F., Yoshimoto T., Nakamura Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet. 1996 Jun;13(2):245–247. doi: 10.1038/ng0696-245. [DOI] [PubMed] [Google Scholar]
  12. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. doi: 10.1126/science.7545954. [DOI] [PubMed] [Google Scholar]
  13. Phelan C. M., Lancaster J. M., Tonin P., Gumbs C., Cochran C., Carter R., Ghadirian P., Perret C., Moslehi R., Dion F. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet. 1996 May;13(1):120–122. doi: 10.1038/ng0596-120. [DOI] [PubMed] [Google Scholar]
  14. Shattuck-Eidens D., McClure M., Simard J., Labrie F., Narod S., Couch F., Hoskins K., Weber B., Castilla L., Erdos M. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA. 1995 Feb 15;273(7):535–541. [PubMed] [Google Scholar]
  15. Teng D. H., Bogden R., Mitchell J., Baumgard M., Bell R., Berry S., Davis T., Ha P. C., Kehrer R., Jammulapati S. Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nat Genet. 1996 Jun;13(2):241–244. doi: 10.1038/ng0696-241. [DOI] [PubMed] [Google Scholar]
  16. Thompson M. E., Jensen R. A., Obermiller P. S., Page D. L., Holt J. T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet. 1995 Apr;9(4):444–450. doi: 10.1038/ng0495-444. [DOI] [PubMed] [Google Scholar]
  17. van den Berg J., Johannsson O., Håkansson S., Olsson H., Borg A. Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer. Br J Cancer. 1996 Nov;74(10):1615–1619. doi: 10.1038/bjc.1996.597. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES